pharma · Asthma · Idiopathic pulmonary fibrosis (IPF)
Chiesi Farmaceutici S.p.A
Chiesi Farmaceutici S.p.A is a pharma organization headquartered in Parma, IT. Primary therapeutic focus areas include Asthma, Idiopathic pulmonary fibrosis (IPF), Mild to moderate asthma, Pulmonary fibrosis, Chronic obs
Company details
- Status
- Public
- HQ
- Via Paradigna, 131, Parma, Emilia-Romagna 43122, IT
- Employees
- 6,080
- Programs
- 20
- Drugs
- 38
- Patents
- 0
CLI-05993AA3-06
Phase 3 · small molecule · Chronic obstructive pulmonary disease (COPD)
CLI-05993AA3-06 for Chronic obstructive pulmonary disease (COPD) is a Phase 3 program (small_molecule) at Chiesi Farmaceutici S.p.A with 1 ClinicalTrials.gov record(s).
Internal code CLI-05993AA3-06
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Chiesi Farmaceutici S.p.A
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Chronic obstructive pulmonary disease (COPD)
- Status
- active
- Trials
- 1